AOD-9604 + CJC-1295 + Ipamorelin Dosage Protocol | PeptideDosages.com

AOD-9604 + CJC-1295 + Ipamorelin (12 mg Blend) Dosage Protocol

AOD-9604 + CJC-1295 + Ipamorelin Dosage Chart

The AOD-9604 + CJC-1295 + Ipamorelin peptide blend is dosed at 200 mcg–400 mcg daily via subcutaneous injection in educational protocols. A 12 mg blend reconstituted with bacteriostatic water yields about 4 mg/mL. This information is for research and educational use only.

Vial contents: 6 mg AOD-9604 + 3 mg CJC-1295 + 3 mg Ipamorelin (12 mg total).

Reconstitute: Add 3.0 mL bacteriostatic water → 4 mg/mL total (2 mg/mL AOD, 1 mg/mL CJC, 1 mg/mL Ip).

Typical daily range: 0.1–0.2 mL once daily (200–400 mcg AOD / 100–200 mcg CJC / 100–200 mcg Ip).

Easy measuring: At 4 mg/mL total, 1 unit = 0.01 mL = 40 mcg total (20 mcg AOD + 10 mcg CJC + 10 mcg Ip).

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

This synergistic blend combines three peptides targeting body composition: AOD-9604 (hGH fragment 177–191) promotes lipolysis without raising IGF-1[1]; CJC-1295 (GHRH analog) produces sustained GH and IGF-1 elevations[2]; and Ipamorelin (ghrelin mimetic) selectively stimulates GH secretion without increasing cortisol or ACTH[3]. Together, these peptides may support lean mass gains and fat reduction[4].

Related research: For distinct compound, component, or formulation evidence and safety context, read AOD-9604 Peptide: Benefits, Uses, Side Effects, Dosage, and Research, Ipamorelin Peptide: Benefits, Uses, Side Effects, Dosage, and Research, and CJC-1295 DAC Peptide: Benefits, Uses, Side Effects, Dosage, and Research. These links are comparisons only; the compounds and formulations should not be treated as interchangeable.

Standard / Gradual Approach (3 mL reconstitution)

Concentration after reconstitution: 2.0 mg/mL AOD-9604 | 1.0 mg/mL CJC-1295 | 1.0 mg/mL Ipamorelin

Week 1

200 mcg AOD / 100 mcg CJC / 100 mcg Ip

10 units (0.10 mL)

Week 2

300 mcg AOD / 150 mcg CJC / 150 mcg Ip

15 units (0.15 mL)

Weeks 3–12

400 mcg AOD / 200 mcg CJC / 200 mcg Ip

20 units (0.20 mL)

Frequency: Inject once daily subcutaneously, preferably in the morning or before bed on an empty stomach. For ≤10‑unit (≤0.10 mL) administrations during titration, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Syringe Math Reference

Using a U-100 insulin syringe (100 units = 1 mL):

1 unit (0.01 mL) = 20 mcg AOD + 10 mcg CJC + 10 mcg Ip

10 units (0.10 mL) = 200 mcg AOD + 100 mcg CJC + 100 mcg Ip

15 units (0.15 mL) = 300 mcg AOD + 150 mcg CJC + 150 mcg Ip

20 units (0.20 mL) = 400 mcg AOD + 200 mcg CJC + 200 mcg Ip

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration (maintenance dose: 0.20 mL/day).

8 weeks (~11.2 mL total): 4 vials

12 weeks (~16.8 mL total): 6 vials

16 weeks (~22.4 mL total): 8 vials

Per week: 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

16 weeks: 112 syringes

8 weeks (4 vials): 12 mL → 2 × 10 mL bottles

12 weeks (6 vials): 18 mL → 2 × 10 mL bottles

16 weeks (8 vials): 24 mL → 3 × 10 mL bottles

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100‑count boxes

12 weeks: 168 swabs → recommend 2 × 100‑count boxes

16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Protocol Overview

Concise summary of the once‑daily regimen.

Goal: Support body composition improvements through combined lipolytic and GH-stimulating mechanisms[4][5].

Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).

Dose Range: 200–400 mcg AOD / 100–200 mcg CJC / 100–200 mcg Ip daily with gradual titration.

Reconstitution: 3.0 mL per 12 mg vial (4 mg/mL total concentration).

Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

Start: 0.10 mL daily (200 mcg AOD / 100 mcg CJC / 100 mcg Ip); increase by ~0.05 mL weekly as tolerated.

Target: 0.20 mL daily (400 mcg AOD / 200 mcg CJC / 200 mcg Ip) by Week 3.

Frequency: Once per day (subcutaneous).

Cycle Length: 8–12 weeks; optional extension to 16 weeks.

Timing: Morning or before bed on an empty stomach; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.

Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days per CDC/USP guidelines[6].

Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each injection; dispose in a sharps container.

Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.

Inject slowly; wait a few seconds before withdrawing the needle.

Document daily dose and site rotation to maintain consistency.

Best administered on an empty stomach (fasting) for optimal GH release.

How This Works

This blend combines three complementary peptides with distinct mechanisms:

AOD-9604 is a modified C-terminal fragment of human growth hormone (amino acids 177–191) that retains the lipolytic and anti-lipogenic properties of GH without stimulating IGF-1 or affecting glucose metabolism[1][7].

CJC-1295 is a long-acting GHRH analog that produces sustained elevations in growth hormone and IGF-1 levels[2], supporting anabolic processes and fat metabolism.

Ipamorelin is a selective ghrelin mimetic that stimulates pulsatile GH secretion without significantly increasing ACTH or cortisol[3], offering a cleaner GH release profile.

Together, these peptides work synergistically to enhance endogenous GH pulsatility and promote favorable changes in body composition similar to exogenous GH therapy[4][5].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

Potential Benefits

Supports reduction in fat mass and enhancement of lipolysis[1][5].

May promote lean mass gains through sustained GH and IGF-1 elevation[2][4].

Selective GH release without significant cortisol or prolactin increases[3].

AOD-9604 shows a placebo-like safety profile in human studies[7][8].

Possible Side Effects

Mild injection-site reactions (redness, itching) with subcutaneous administration.

Transient flushing or warmth following injection.

Occasional headache or lightheadedness during initial use.

Water retention (typically mild) with sustained GH elevation.

Lifestyle Factors

Complementary strategies for best outcomes.

Pair with a balanced, protein-forward diet tailored to energy needs.

Combine resistance training and aerobic activity to reinforce metabolic adaptations.

Prioritize quality sleep (7–9 hours) to maximize endogenous GH release.

Manage stress to optimize hormonal balance and recovery.

Stay hydrated and maintain consistent meal timing.

Injection Technique

General subcutaneous guidance from clinical best-practice resources[9].

Clean the vial stopper and skin with alcohol; allow to dry.

Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[10][11].

Do not aspirate for subcutaneous injections; inject slowly and steadily[10].

Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[12].

Dispose of used syringes in an approved sharps container; follow local disposal regulations.

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References

Journal of Endocrinology & Metabolism (2014) — Safety and metabolism of AOD9604: novel nutraceutical ingredient for improved metabolic health View Source

Journal of Clinical Endocrinology & Metabolism (PubMed) — Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults View Source

European Journal of Endocrinology (PubMed) — Ipamorelin: the first selective growth hormone secretagogue View Source

Translational Andrology and Urology (PMC) — Role of growth hormone secretagogues in body composition management View Source

Endocrinology (OUP) — hGH and AOD-9604: lipid metabolism and beta-adrenergic pathway insights View Source

CDC — Preventing unsafe injection practices: multi-dose vial handling guidelines View Source

Journal of Endocrinology & Metabolism (2013) — Safety and tolerability of the hexadecapeptide AOD9604 in humans View Source

Obesity Pharmacotherapy Review (PMC) — AOD-9604 clinical trial overview and weight loss outcomes View Source

Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route View Source

CDC — Vaccine administration: subcutaneous route (angle/site guidance) View Source

MedlinePlus — Subcutaneous injections: patient instructions and technique View Source

NCBI Bookshelf — Best practices for injection: asepsis, preparation, and administration View Source

Additional Research and Background

These sources provide related context and are not presented as support for a specific statement above.

Central & Peripheral Anti-Obesity Targets (PMC) — AOD-9604 RCT summary and mechanistic overview View Source

PubMed — Metabolic studies of AOD-9604 in obese rodents (oral dosing, fat oxidation) View Source

Related research, protocols, and guides

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.

Research overview

AOD-9604 Peptide: Benefits, Uses, Side Effects, Dosage, and Research

Ipamorelin Peptide: Benefits, Uses, Side Effects, Dosage, and Research

CJC-1295 DAC Peptide: Benefits, Uses, Side Effects, Dosage, and Research

Related protocols and comparisons

AOD-9604 (2 mg Vial) Dosage Protocol

AOD-9604 (5 mg Vial) Dosage Protocol

Ipamorelin (5 mg Vial) Dosage Protocol

Ipamorelin (10 mg Vial) Dosage Protocol

CJC-1295 NO DAC + Ipamorelin (10 mg Blend) Dosage Protocol

Tesamorelin 5mg + Ipamorelin 5mg (10mg Blend) Dosage Protocol

CJC-1295 DAC (5 mg) + Ipamorelin (5 mg) Stack Dosage Protocol

CJC-1295 DAC (2 mg) + Ipamorelin (5 mg) Stack Dosage Protocol

Practical guides

Peptide Blend Dosages

Peptide Dosage & Reconstitution Calculator

How to Reconstitute Peptides

Syringe & Measurement Guide

Peptide Storage Guide

Peptide Dosage Chart